Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- CD38 Positive
- Plasma Cell Myeloma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
OUTLINE: This is a dose-escalation study of 211At-OKT10-B10. Patients receive 211At-OKT10-B10 intravenously (IV) continuously on days -7 to -4 and melphalan via infusion on day -2. Patients then undergo peripheral blood stem cell (PBSC) transplantation on day 0. After completion of study treatment, ...
OUTLINE: This is a dose-escalation study of 211At-OKT10-B10. Patients receive 211At-OKT10-B10 intravenously (IV) continuously on days -7 to -4 and melphalan via infusion on day -2. Patients then undergo peripheral blood stem cell (PBSC) transplantation on day 0. After completion of study treatment, patients are followed for 30 days, between 80 and 90 days, at 6, 9, 12, 18, and 24 months, and then annually thereafter.
Tracking Information
- NCT #
- NCT04466475
- Collaborators
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- Investigators
- Principal Investigator: Damian J. Green Fred Hutch/University of Washington Cancer Consortium
Get Well Soon